Dalbavancin in clinical practice : a particular place for the elderly?
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
We investigate dalbavancin efficiency and tolerance among elderly in Grenoble-Alpes 32 university hospital. Among the 65 patients who received dalbavancin, 51% (33) were considered as old. Patients presented mainly bones and joint infections (52%), surgical site infection 34 (31%), and infective endocarditis (IE) (8%). Clinical cure was confirmed for 79% of old 35 patients at 1, 3, and 6 months. Six adverse events (9%) were reported after 36 dalbavancin's administration, but each time in combination with other antibiotics. 37 Dalbavancin had a significant effectiveness and safety profile and represents a real 38 therapeutic option in the management of deep and complex infections of elderly patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 41(2022), 6 vom: 26. Juni, Seite 977-979 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wackenheim, Chloé [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
61036-62-2 |
|---|
| Anmerkungen: |
Date Completed 30.05.2022 Date Revised 30.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10096-022-04427-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34000780X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34000780X | ||
| 003 | DE-627 | ||
| 005 | 20231226004156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10096-022-04427-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1133.xml |
| 035 | |a (DE-627)NLM34000780X | ||
| 035 | |a (NLM)35471751 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wackenheim, Chloé |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dalbavancin in clinical practice |b a particular place for the elderly? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.05.2022 | ||
| 500 | |a Date Revised 30.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a We investigate dalbavancin efficiency and tolerance among elderly in Grenoble-Alpes 32 university hospital. Among the 65 patients who received dalbavancin, 51% (33) were considered as old. Patients presented mainly bones and joint infections (52%), surgical site infection 34 (31%), and infective endocarditis (IE) (8%). Clinical cure was confirmed for 79% of old 35 patients at 1, 3, and 6 months. Six adverse events (9%) were reported after 36 dalbavancin's administration, but each time in combination with other antibiotics. 37 Dalbavancin had a significant effectiveness and safety profile and represents a real 38 therapeutic option in the management of deep and complex infections of elderly patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Anti-bacterial agents | |
| 650 | 4 | |a Arthritis | |
| 650 | 4 | |a Bone diseases, infectious | |
| 650 | 4 | |a Comorbidity | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Teicoplanin |2 NLM | |
| 650 | 7 | |a 61036-62-2 |2 NLM | |
| 650 | 7 | |a dalbavancin |2 NLM | |
| 650 | 7 | |a 808UI9MS5K |2 NLM | |
| 700 | 1 | |a Le Maréchal, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Pluchart, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Gavazzi, Gaëtan |e verfasserin |4 aut | |
| 700 | 1 | |a Blanc, Myriam |e verfasserin |4 aut | |
| 700 | 1 | |a Caspar, Yvan |e verfasserin |4 aut | |
| 700 | 1 | |a Pavese, Patricia |e verfasserin |4 aut | |
| 700 | 0 | |a GRIC |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology |d 1988 |g 41(2022), 6 vom: 26. Juni, Seite 977-979 |w (DE-627)NLM012620742 |x 1435-4373 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2022 |g number:6 |g day:26 |g month:06 |g pages:977-979 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10096-022-04427-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2022 |e 6 |b 26 |c 06 |h 977-979 | ||